Since its inception, TVM Capital has raised more than €1.3 billion in investment capital, and the firm is currently investing from its sixth generation of funds. To offer a higher degree of flexibility in portfolio diversification to investors, our fifth fund generation marked a split into dedicated industry-specific fund entities for life sciences/healthcare and technology investments, respectively. In all its funds, TVM Capital has a strong global base of Limited Partners, including investors from Europe, the United States and Asia.
As with previous funds, TVM LSV VI maintains a strong emphasis on investments in the fields of drug discovery and development and is funding companies through all stages and maturities in the U.S. and Europe.
TVM V Information Technology
TVM V IT invests in early and later stage European and US companies in the areas of business software, semiconductors and components, wireless and telecommunications, media content and environmental technologies.
This dedicated life sciences fund focused primarily on early stage investments throughout Europe and the United States. The sector focus remained unchanged from previous fund entities, with a strong emphasis on platform technologies that enhance drug discovery, integrated drug discovery, drug delivery and drug development companies. IPOs from this fund have included Addex, Sirtris and Jerini. Strategic corporate buyers bought Jerini and Sirtris in 2008.